前列腺特异性抗原密度在前列腺癌诊断流程中的应用
基于STHLM3人群中5291例PSA≥3 ng/ml且行超声引导前列腺体积测量的男性,分析PSA密度与活检结局的关系。PSA密度与临床显著前列腺癌(Gleason评分≥7)风险相关,加入模型后判别能力改善(AUC 0.75 vs 0.73,P<0.05);PSA密度≤0.07 ng/ml²可节省19.7%活检但漏诊6.9% csPCa。
要点
- PSA密度与临床显著前列腺癌风险相关(未调整OR 1.06,95%CI 1.05-1.07)。
- 加入PSA密度后模型判别能力改善(AUC 0.75 vs 0.73,P<0.05)。
- PSA密度≤0.07 ng/ml²可节省19.7%活检,漏诊6.9% csPCa。
核心结论
- PSA密度可能为活检决策提供信息,使部分男性免于前列腺活检相关疾病负担及低级别前列腺癌诊断。
研究设计与样本
- 基于STHLM3人群研究,分析5291例PSA≥3 ng/ml且行超声引导前列腺体积测量男性的活检结局。
- 采用百分比和回归模型分析,PSA密度为总PSA(ng/ml)除以前列腺体积(ml)。
- 主要终点为临床显著前列腺癌,定义为Gleason评分≥7。
主要发现
- PSA密度中位数为0.10 ng/ml²(IQR 0.075-0.14)。
- PSA密度与csPCa风险相关:未调整OR 1.06(95%CI 1.05-1.07),调整年龄、家族史、既往活检、总PSA及游离/总PSA后OR 1.07(95%CI 1.06-1.08)。
- 将PSA密度加入含其他临床信息的模型后,对csPCa的判别能力改善(AUC 0.75 vs 0.73,P<0.05)。
- Gleason评分6(ISUP 1)的比例在PSA密度各分层间相似。
- 对PSA密度≤0.07 ng/ml²的男性省略前列腺活检可节省19.7%的活检操作,同时漏诊6.9%的csPCa。
临床怎么用
- PSA密度可能用于辅助活检决策,帮助识别可免于活检的男性。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Screening for prostate cancer using prostate-specific antigen (PSA) alone leads to un-necessary biopsying and overdiagnosis. PSA density is easily accessible, but early evidence on its use for biopsy decisions was conflicting and use of PSA density is not commonly recommended in guidelines. METHODS: We analyzed biopsy outcomes in 5291 men in the population-based STHLM3 study with PSA ≥ 3 ng/ml and ultrasound-guided prostate volume measurements by using percentages and regression models. PSA density was calculated as total PSA (ng/ml) divided by prostate volume (ml). Main endpoint was clinically significant cancer (csPCa) defined as Gleason Score ≥ 7. RESULTS: The median PSA-density was 0.10 ng/ml2 (IQR 0.075-0.14). PSA-density was associated with the risk of finding csPCa both with and without adjusting for the additional clinical information age, family history, previous biopsies, total PSA and free/total PSA (OR 1.06; 95% CI:1.05-1.07 and OR 1.07, 95% CI 1.06-1.08). Discrimination for csPCa was better when PSA density was added to a model with additional clinical information (AUC 0.75 vs. 0.73, P < 0.05). The proportion of men with Gleason Score 6 (ISUP 1) was similar across stratas of PSA-density. Omitting prostate biopsy for men with PSA-density ≤0.07 ng/ml2 would save 19.7% of biopsy procedures, while missing 6.9% of csPCa. PSA-density cutoffs of 0.10 ng/ml2 and 0.15 ng/ml2 resulted in detection of 77% (729/947) and 49% (461/947) of Gleason Score ≥7 tumors. CONCLUSIONS: PSA-density might inform biopsy decisions, and spare some men from the morbidity associated with a prostate biopsy and diagnosis of low-grade prostate cancer.
引用
- Nordström T, Akre O, Aly M, et al. Prostate-specific antigen (PSA) density in the diagnostic algorithm of prostate cancer. Prostate Cancer Prostatic Dis. 2017. PMID: 29259293. doi:10.1038/s41391-017-0024-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。